PriceTargets.com logo

NASDAQ:BMEA - Biomea Fusion Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.33
  • Forecasted Upside: 98.89 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$13.24 As of 07/23/2021 01:00 AM ET
▼ -0.2 (-1.49%)

This chart shows the closing price for BMEA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biomea Fusion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMEA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMEA

Analyst Price Target is $26.33
▲ +98.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Biomea Fusion in the last 3 months. The average price target is $26.33, with a high forecast of $27.00 and a low forecast of $26.00. The average price target represents a 98.89% upside from the last price of $13.24.

This chart shows the closing price for BMEA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Biomea Fusion.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2021JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Medium
5/11/2021Piper SandlerInitiated CoverageOverweight$27.00High
5/11/2021Jefferies Financial GroupInitiated CoverageBuy$26.00High
(Data available from 7/23/2016 forward)
Biomea Fusion logo
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Read More

Today's Range

Now: $13.24
Low: $13.09
High: $13.50

50 Day Range

MA: $16.94
Low: $13.38
High: $20.93

52 Week Range

Now: $13.24
Low: $12.53
High: $22.22

Volume

21,186 shs

Average Volume

121,276 shs

Market Capitalization

$380.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biomea Fusion?

The following equities research analysts have issued reports on Biomea Fusion in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for BMEA.

What is the current price target for Biomea Fusion?

3 Wall Street analysts have set twelve-month price targets for Biomea Fusion in the last year. Their average twelve-month price target is $26.33, suggesting a possible upside of 98.9%. Piper Sandler has the highest price target set, predicting BMEA will reach $27.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $26.00 for Biomea Fusion in the next year.
View the latest price targets for BMEA.

What is the current consensus analyst rating for Biomea Fusion?

Biomea Fusion currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMEA will outperform the market and that investors should add to their positions of Biomea Fusion.
View the latest ratings for BMEA.

What other companies compete with Biomea Fusion?

Other companies that are similar to Biomea Fusion include Indivior, Connect Biopharma, ADC Therapeutics, Madrigal Pharmaceuticals, COMPASS Pathways, Aurinia Pharmaceuticals, Amneal Pharmaceuticals, Supernus Pharmaceuticals, PureTech Health, Day One Biopharmaceuticals, Nurix Therapeutics, Innoviva, Heron Therapeutics, Applied Molecular Transport and Zealand Pharma A/S.

How do I contact Biomea Fusion's investor relations team?

The company's listed phone number is 650-980-9099. The official website for Biomea Fusion is www.biomeafusion.com.